Business Description
Homology Medicines Inc
NAICS : 325412
SIC : 2834
ISIN : US4380831077
Description
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 62.71 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -11.18 | |||||
| Beneish M-Score | -4.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -30.2 | |||||
| 3-Year EBITDA Growth Rate | 15.9 | |||||
| 3-Year EPS without NRI Growth Rate | 11.5 | |||||
| 3-Year FCF Growth Rate | 7.9 | |||||
| 3-Year Book Growth Rate | -31.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.01 | |||||
| 9-Day RSI | 55.55 | |||||
| 14-Day RSI | 56.14 | |||||
| 6-1 Month Momentum % | -25.47 | |||||
| 12-1 Month Momentum % | -7.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.25 | |||||
| Quick Ratio | 7.25 | |||||
| Cash Ratio | 7.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.9 | |||||
| Shareholder Yield % | 163.98 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -7967.3 | |||||
| Net Margin % | -9771.71 | |||||
| FCF Margin % | -8321.47 | |||||
| ROE % | -92.52 | |||||
| ROA % | -68.85 | |||||
| ROIC % | -232.8 | |||||
| ROC (Joel Greenblatt) % | -550.15 | |||||
| ROCE % | -64.01 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.6 | |||||
| PB Ratio | 0.04 | |||||
| Price-to-Tangible-Book | 0.04 | |||||
| EV-to-EBIT | 0.85 | |||||
| EV-to-EBITDA | 0.86 | |||||
| EV-to-Forward-EBITDA | -0.02 | |||||
| EV-to-Revenue | -67.75 | |||||
| EV-to-Forward-Revenue | 0.94 | |||||
| EV-to-FCF | 0.81 | |||||
| Price-to-Net-Current-Asset-Value | 0.04 | |||||
| Price-to-Net-Cash | 0.04 | |||||
| Earnings Yield (Greenblatt) % | 117.65 | |||||
| FCF Yield % | -3195.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Homology Medicines Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.076 | ||
| EPS (TTM) (€) | -32.612 | ||
| Beta | 0 | ||
| Volatility % | 99.4 | ||
| 14-Day RSI | 56.14 | ||
| 14-Day ATR (€) | 0.81373 | ||
| 20-Day SMA (€) | 14.638499 | ||
| 12-1 Month Momentum % | -7.71 | ||
| 52-Week Range (€) | 5.651999 - 22.679999 | ||
| Shares Outstanding (Mil) | 3.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Homology Medicines Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Homology Medicines Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Homology Medicines Inc Frequently Asked Questions
What is Homology Medicines Inc(FRA:35H)'s stock price today?
The current price of FRA:35H is €14.94. The 52 week high of FRA:35H is €22.68 and 52 week low is €5.65.
When is next earnings date of Homology Medicines Inc(FRA:35H)?
The next earnings date of Homology Medicines Inc(FRA:35H) is 2025-03-08 Est..
Does Homology Medicines Inc(FRA:35H) pay dividends? If so, how much?
Homology Medicines Inc(FRA:35H) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers